Keepin touch

Whether you have a question, comment, suggestion or any problem falling within the competence of the Government, send us your message and we will try to respond as soon as possible. If your problem does not fall within our competence, we will forward your message to the competent institution.

The Government of the Republic of Serbia

In the service of citizens

RDIF, Torlak Institute agree to produce Sputnik V vaccine in Serbia

Belgrade/Moscow, 25 March 2021

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Institute of Virology, Vaccines and Serums Torlak announced today that they reached an agreement on the production of Sputnik V, the world’s first registered vaccine against coronavirus, in Serbia.

According to a statement from the Office of the Minister without portfolio in charge of innovation and technological development, Serbia will become the first country in Southern Europe to produce Sputnik V. The vaccine could be exported to other countries of the region at a later stage.

The production of Sputnik V is due to start by May 2021 at facilities of Institute Torlak. Torlak is Serbia’s national vaccine producer supplying healthcare institutions in the country with vaccines for the compulsory immunisation programme.

The first batch of Sputnik V was delivered to Serbia on December 30, 2020.

The vaccination against coronavirus with the Russian vaccine started in Serbia on 6 January 2021.

To date, Sputnik V has been registered in 56 countries globally with a total population of over 1.5 billion people. Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals.

The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in the course of the vaccination.